Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

UBS Warburg Raises Estimates for Millennium Pharmaceuticals


Millennium Pharmaceuticals (MLNM) shares rose after the Food and Drug Administration approved the company's Velcase treatment for multiple myeloma, a bone marrow cancer. UBS Warburg raised its estimates and price target on the news.

Analyst Meirav Chovav says the approval of Velcade is a quarter and a half ahead of her expectations. She raised her 2003 $18 million Velcade sales estimate to $43 million. She sees Velcade sales of $180 million in 2004 and $285 million in 2005. She narrowed her $1.05 2003 loss per share estimate to a $1.00 loss, and sees a loss of 73 cents in 2004. She also raised her $10 price target to $14.

However, Chovav remains cautious on Millennium shares due to near term Integrilin inventories and concerns over the longer term financial risk related to the company's cash burn. She maintained a neutral rating on the stock.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus